<DOC>
	<DOCNO>NCT01714726</DOCNO>
	<brief_summary>The study design evaluate clinical efficacy safety MEDI2070 compare placebo . Investigational product administer intravenous infusion double-blind period , subcutaneous injection open-label period</brief_summary>
	<brief_title>Evaluation Efficacy Safety MEDI2070 Patients With Active , Moderate-to-severe Crohn 's Disease .</brief_title>
	<detailed_description>This two-part Phase 2a study compromise 12-week , double-blind , placebo-controlled , treatment period follow 100-week , open label , treatment period evaluate short-term efficacy , short- long-term safety MEDI2070 subject moderate severe , active CD fail intolerant anti-TNFα therapy determine investigator . Approximately 120 subject randomize 1:1 ratio initially receive fix IV dose MEDI2070 placebo Week 0 ( Day1 ) Week 4 ( Day 29 ) 12-week , double-blind , placebo-controlled , treatment period . At completion double-blind , placebo-controlled , treatment period ( Week 12 ) , subject option enter 100-week , open-label , treatment period receive open-label MEDI2070 ( SC ) Q4W ( Week 12 Week 112 ) . Subjects follow safety 3 visit 28 week last dose IP . Subjects also contact phone 36 week last dose IP safety .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Diagnosed ileal , ileocolonic , colonic CD least 6 month prior screen . Men woman age 18 65 year time screen . Moderatesever active Crohn 's Disease ( CD ) , define Crohn 's Disease Activity Index ( CDAI ) score high equal 220 low equal 450 Day 1 . No known history active tuberculosis ( TB ) . Received least one antiTNFα agent treatment CD initially respond . Pregnant breastfeed woman . Presence ileostomy and/or colostomy . Short bowel syndrome . Bowel perforation obstruction . History cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MEDI2070</keyword>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>moderate severe Crohn 's disease</keyword>
</DOC>